Shares of Evolent Health, Inc. (NYSE:EVH – Get Rating) have been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $40.29.
Several equities research analysts have recently commented on the company. Guggenheim assumed coverage on Evolent Health in a report on Tuesday, March 29th. They set a “buy” rating and a $43.00 target price for the company. Canaccord Genuity Group upped their target price on Evolent Health from $40.00 to $45.00 in a report on Monday, May 9th. Zacks Investment Research raised Evolent Health from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Wednesday, May 4th. BTIG Research upped their target price on Evolent Health from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday, March 25th. Finally, Piper Sandler reduced their target price on Evolent Health from $37.00 to $35.00 and set a “na” rating for the company in a report on Tuesday.
In related news, COO Steve Tutewohl sold 1,918 shares of the stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $27.30, for a total value of $52,361.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.20% of the stock is currently owned by corporate insiders.
EVH opened at $29.43 on Friday. Evolent Health has a one year low of $18.33 and a one year high of $34.60. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.21 and a current ratio of 1.21. The stock’s fifty day moving average is $29.58 and its 200-day moving average is $27.32. The company has a market capitalization of $2.70 billion, a PE ratio of -77.45 and a beta of 2.07.
Evolent Health (NYSE:EVH – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The technology company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.20. Evolent Health had a negative return on equity of 0.86% and a negative net margin of 3.35%. The company had revenue of $297.10 million for the quarter, compared to the consensus estimate of $286.81 million. During the same quarter in the previous year, the business earned ($0.06) EPS. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, equities research analysts forecast that Evolent Health will post -0.21 EPS for the current fiscal year.
Evolent Health Company Profile (Get Rating)
Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.
- Get a free copy of the StockNews.com research report on Evolent Health (EVH)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.